Also, Rautenberg and colleagues proposed peripheral blood WT1 expression as a pre-transplant MRD marker, predicting post-transplant outcome and, hence, improving peri-transplant management in high-risk AML/MDS patients [34]. The gene discussed is WT1; the disease is myelodysplastic syndrome.